Construction of chondroitin sulfate microarray - project title: construction of chondroitin sulfate microarray the proposal is aimed to develop a high throughput method to study the interactions…
Ended Project Grant Awarded Last action
- Award ID
- R43GM140693
- Recipient
-
Glycan Therapeutics Corporation UEI KYG3DZSMH4R7
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $663,268
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Place of performance
- Raleigh, NC 27606, USA
Award details come from USAspending.gov.
Description
Construction of chondroitin sulfate microarray - project title: construction of chondroitin sulfate microarray the proposal is aimed to develop a high throughput method to study the interactions between chondroitin sulfate (CS) and proteins. CS is a member of glycosaminoglycan family displaying a wide range of biological functions. Glycan therapeutics is a company specialized in CS and other glycosaminoglycan related research products. In this phase I sbir proposal, a CS microarray technique will be constructed. The strength of the company is capable of synthesizing structurally defined CS oligosaccharides using the enzymatic method, allowing to synthesize gram-scale of CS oligosaccharide. A single specific aim is proposed in the current application, which to build CS-microarray analysis technique covering 30 different oligosaccharides. Three experiments to support the quality control of the technology are proposed. First experiment is to couple a chemical linker to the synthesized CS oligosaccharides to allow affixation of the oligosaccharides on the array chip. Second experiment is to prepare eight fluorescently labeled CS oligosaccharides to evaluate the efficiency for the affixation to the chip. Third experiment is to identify a CS-binding protein to serve as a positive control for the CS-microarray analysis. In the phase II studies, the number of oligosaccharides array slides will be expanded to 200 to fully represent the structures of CS isolated from natural sources. The success will lead to a convenient approach for improving research in glycosciences.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $331,634 | |
| Original award | $331,634 |
Quick answers
Who received award R43GM140693?
R43GM140693 was awarded to Glycan Therapeutics Corporation by National Institute of General Medical Sciences (National Institutes of Health) on May 1, 2022.
How much is award R43GM140693 worth?
$663,268 has been obligated on R43GM140693.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award